© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
Boston--The fact that prostate cancer recurrence can be indolent may actually be detrimental to the development of drugs for patients in whom recurrence is life-threatening.